-
公开(公告)号：US20140065099A1
公开(公告)日：2014-03-06
申请号：US13984157
申请日：2012-02-15
IPC分类号： A61K31/706 , A61K45/06
CPC分类号： A61K31/706 , A61K31/05 , A61K31/405 , A61K31/473 , A61K31/502 , A61K31/7064 , A61K31/7088 , A61K45/06 , C12N15/1137 , C12N2310/14
摘要： The present invention provides methods of treating various disorders associated with mitochondrial dysfunction, including but not limited to metabolic disorders, neurodegenerative diseases, chronic inflammatory diseases, and diseases of aging.
摘要翻译： 本发明提供了治疗与线粒体功能障碍相关的各种疾病的方法，包括但不限于代谢紊乱，神经变性疾病，慢性炎性疾病和衰老疾病。
-
2.发明申请Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders 审中-公开用于治疗或预防肥胖，胰岛素抵抗障碍和线粒体相关疾病的方法和相关组合物公开(公告)号：US20070149466A1
公开(公告)日：2007-06-28
申请号：US11374295
申请日：2006-03-16
申请人： Michael Milburn , Jill Milne , Johan Auwerx , Carmen Argmann , Marie Lagouge , Michelle Dipp
发明人： Michael Milburn , Jill Milne , Johan Auwerx , Carmen Argmann , Marie Lagouge , Michelle Dipp
IPC分类号： A61K31/7056 , A61K31/05
CPC分类号： A61K31/05 , A23L33/10 , A23L33/30 , A61K31/00 , A61K31/7056 , A61K45/06 , A61K2300/00
摘要： Provided herein are methods and compositions for treating or preventing metabolic disorders, such as obesity and diabetes. Methods may comprise modulating the activity or level of a sirtuin, such as SIRT1 or Sir2. Exemplary methods comprise contacting a cell with a sirtuin activating compound, such as a flavone, stilbene, flavanone, isoflavone, catechin, chalcone, tannin or anthocyanidin, or an inhibitory compound, such as nicotinamide.
摘要翻译： 本文提供了用于治疗或预防代谢性疾病如肥胖症和糖尿病的方法和组合物。 方法可以包括调节sirtuin的活性或水平，例如SIRT1或Sir2。 示例性方法包括使细胞与沉默调节蛋白激活化合物如黄酮，芪，黄酮酮，异黄酮，儿茶素，查耳酮，单宁或花青素或抑制性化合物如烟酰胺接触。
-
公开(公告)号：US09872850B2
公开(公告)日：2018-01-23
申请号：US13336841
申请日：2011-12-23
申请人： Christopher Lawrence Rinsch , William Blanco-Bose , Bernard Schneider , Charles Thomas , Carmen Sandi , Johan Auwerx , Penelope Andreux , Richardus Houtkooper , Eija Pirinen , Laurent Mouchiroud , David Genoux
发明人： Christopher Lawrence Rinsch , William Blanco-Bose , Bernard Schneider , Charles Thomas , Carmen Sandi , Johan Auwerx , Penelope Andreux , Richardus Houtkooper , Eija Pirinen , Laurent Mouchiroud , David Genoux
IPC分类号： A61K31/366 , A61K36/185 , A61K31/7048 , A61K9/00 , A61K31/352 , A23L33/105
CPC分类号： A61K31/366 , A23L33/105 , A23V2002/00 , A61K9/0014 , A61K9/0053 , A61K9/0056 , A61K31/352 , A61K31/7048 , A61K36/185 , Y02A50/401
摘要： Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.
-
公开(公告)号：US09180134B2
公开(公告)日：2015-11-10
申请号：US14239198
申请日：2012-08-20
IPC分类号： A61K48/00 , A61K31/65 , A61K31/713 , C12N15/113 , G01N33/50 , A61K31/165 , A61K49/00 , C12Q1/68
CPC分类号： A61K31/65 , A61K31/165 , A61K31/713 , A61K49/0008 , C12N15/113 , C12N2310/14 , C12Q1/6897 , G01N33/5023 , G01N33/5079 , G01N33/5085
摘要： The present invention relates to methods of increasing lifespan, delaying aging, and/or preventing or treating an age-related disease or a mitochondrial disease in a subject, comprising inducing a nuclear-mitochondrial OXPHOS protein dyssynchrony, including inhibiting the mitochondrial translation machinery function, as well as methods for screening agents that are able to increase lifespan, inhibit or delay aging, and/or prevent or treat an age-related disease or disorder, or a mitochondrial disease or disorder, in a subject.
摘要翻译： 本发明涉及增加使用寿命，延缓衰老和/或预防或治疗受试者中与年龄有关的疾病或线粒体疾病的方法，包括诱导核线粒体OXPHOS蛋白质不同步，包括抑制线粒体翻译机制功能， 以及能够增加受试者的寿命，抑制或延缓衰老和/或预防或治疗年龄相关的疾病或病症或线粒体疾病或病症的筛选剂的方法。
-
公开(公告)号：US20140187611A1
公开(公告)日：2014-07-03
申请号：US14239198
申请日：2012-08-20
IPC分类号： A61K31/65 , A61K49/00 , G01N33/50 , C12N15/113 , C12Q1/68
CPC分类号： A61K31/65 , A61K31/165 , A61K31/713 , A61K49/0008 , C12N15/113 , C12N2310/14 , C12Q1/6897 , G01N33/5023 , G01N33/5079 , G01N33/5085
摘要： The present invention relates to methods of increasing lifespan, delaying aging, and/or preventing or treating an age-related disease or a mitochondrial disease in a subject, comprising inducing a nuclear-mitochondrial OXPHOS protein dyssynchrony, including inhibiting the mitochondrial translation machinery function, as well as methods for screening agents that are able to increase lifespan, inhibit or delay aging, and/or prevent or treat an age-related disease or disorder, or a mitochondrial disease or disorder, in a subject.
摘要翻译： 本发明涉及增加使用寿命，延缓衰老和/或预防或治疗受试者中与年龄有关的疾病或线粒体疾病的方法，包括诱导核线粒体OXPHOS蛋白质不同步，包括抑制线粒体翻译机制功能， 以及能够增加受试者的寿命，抑制或延缓衰老和/或预防或治疗年龄相关的疾病或病症或线粒体疾病或病症的筛选剂的方法。
-
6.发明申请NCoR1 is a Physiological Modulator of Muscle Mass and Oxidative Function 审中-公开NCoR1是肌肉质量和氧化功能的生理调节剂公开(公告)号：US20140147434A1
公开(公告)日：2014-05-29
申请号：US14116095
申请日：2012-05-07
IPC分类号： A61K39/395 , A61K31/713
CPC分类号： A61K39/3955 , A61K31/713 , A61K38/1709
摘要： The present invention provides methods of increasing muscle mass and muscle mitochondrial oxidative metabolism. Additionally, the invention provides treating various disorders associated with mitochondrial dysfunction, including but not limited to metabolic disorders, muscular dystrophy disorders, neurodegenerative diseases, chronic inflammatory diseases, and diseases of aging.
摘要翻译： 本发明提供了增加肌肉质量和肌肉线粒体氧化代谢的方法。 另外，本发明提供治疗与线粒体功能障碍相关的各种疾病，包括但不限于代谢紊乱，肌营养不良症，神经变性疾病，慢性炎性疾病和老化疾病。
-
公开(公告)号：US20100055066A1
公开(公告)日：2010-03-04
申请号：US11665379
申请日：2005-10-14
申请人： Kazuo Suzuki , Kaoru Sakai , Shinichi Ishii , Kanami Sugimoto , Johan Auwerx , Mitsuhiro Watanabe
发明人： Kazuo Suzuki , Kaoru Sakai , Shinichi Ishii , Kanami Sugimoto , Johan Auwerx , Mitsuhiro Watanabe
IPC分类号： A61K31/785 , A61P43/00
CPC分类号： A61K31/787 , A61K31/785
摘要： According to the present invention, an agent for prophylactic and/or therapeutic treatment of diabetes comprising a substance inhibiting activity of farnesoid X receptor as an active ingredient can be provided.
摘要翻译： 根据本发明，可以提供用于预防和/或治疗治疗糖尿病的药物，其包括法尼酯X受体的物质抑制活性作为活性成分。
-
公开(公告)号：US20080249103A1
公开(公告)日：2008-10-09
申请号：US11981524
申请日：2007-10-30
申请人： Markku Laakso , Teemu Kuulasmaa , Johan Auwerx , Christoph Westphal , Peter Elliott , Karl D. Normington , Olivier Boss , Andre Iffland , Siva Lavu
发明人： Markku Laakso , Teemu Kuulasmaa , Johan Auwerx , Christoph Westphal , Peter Elliott , Karl D. Normington , Olivier Boss , Andre Iffland , Siva Lavu
IPC分类号： A61K31/496 , C12Q1/68 , A61K31/498 , A61K31/429
CPC分类号： G01N33/502 , C12Q1/6883 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172 , G01N33/5023 , G01N2800/042
摘要： Provided herein are methods for diagnosis and prognosis using polymorphic variants of sirtuins. Such polymorphic may be used, for example, to identify subjects that would be responsive to treatment with a sirtuin modulating compound and/or subjects that are suffering from or susceptible to a disease mediated by a sirtuin. Also provided are methods for determining the predictive value of a sirtuin polymorphic variant, methods for evaluating sirtuin modulating compounds, and methods for determining appropriate dosage and/or treatment regimens for subjects having one or more sirtuin polymorphic variants. Screening methods for identifying sirtuin modulating compounds using polymorphic variants of a sirtuin are also provided.
摘要翻译： 本文提供了使用sirtuins的多态性变体进行诊断和预后的方法。 这样的多晶型物可以用于例如鉴定对用沉默调节蛋白调节化合物和/或患有或易感于由沉默调节蛋白调节的疾病的受试者来治疗的受试者。 还提供了用于确定沉默调节蛋白多态性变体的预测值的方法，用于评估沉默调节蛋白调节化合物的方法，以及用于确定具有一种或多种沉默调节蛋白多态性变体的受试者的适当剂量和/或治疗方案的方法。 还提供了使用沉默调节蛋白的多态变体鉴定沉默调节蛋白调节化合物的筛选方法。
-
公开(公告)号：US20080031968A1
公开(公告)日：2008-02-07
申请号：US11392914
申请日：2006-03-30
申请人： Antonio C. Bianco , Johan Auwerx , Marcelo A. Christoffolete , Sander Houten , Brian W. Kim , Philip Reed Larsen , Mitsuhiro Watanabe
发明人： Antonio C. Bianco , Johan Auwerx , Marcelo A. Christoffolete , Sander Houten , Brian W. Kim , Philip Reed Larsen , Mitsuhiro Watanabe
IPC分类号： A61K35/00 , C12Q1/18 , G01N33/53 , G01N33/567
CPC分类号： G01N33/78 , G01N2333/902 , G01N2500/10
摘要： The present invention is directed to methods of treating a human for a variety of conditions by administering an agonist of the G protein coupled receptor TGR5. In addition, the invention includes methods for determining whether a test compound is likely to be effective in treating one of these conditions by assaying it for its ability to raise intracellular iodothyronine deiodinase levels or for its ability to bind to and activate TGR5.
摘要翻译： 本发明涉及通过施用G蛋白偶联受体TGR5的激动剂来治疗各种病症的人的方法。 此外，本发明包括通过测定其提高细胞内碘甲腺氨酸脱碘酶水平或其结合和激活TGR5的能力的能力来测定测试化合物是否可能有效治疗这些病症之一的方法。
-
10.发明申请公开(公告)号：US20070191259A1
公开(公告)日：2007-08-16
申请号：US10568637
申请日：2004-08-20
申请人： Johan Auwerx , Francesca Frigerio , Stefan Fumagalli , Sara Kozma , Frederic Picard , Melanie Sticker-Jantscheff , George Thomas , Sung Um , Mitsuhiro Watanabe
发明人： Johan Auwerx , Francesca Frigerio , Stefan Fumagalli , Sara Kozma , Frederic Picard , Melanie Sticker-Jantscheff , George Thomas , Sung Um , Mitsuhiro Watanabe
IPC分类号： C12Q1/68 , G01N33/48 , G01N33/537 , C12Q1/48
CPC分类号： G01N33/6893 , C12Q1/485 , G01N2500/00 , G01N2500/04 , G01N2800/042
摘要： This invention provides screening methods for agents effective in treating insulin resistance through specific inhibition of S6 kinase 1 activity. Also provided are methods of treating insulin resistance by administering an effective amount of an inhibitor specific for S6 kinase 1.
摘要翻译： 本发明提供了通过特异性抑制S6激酶1活性有效治疗胰岛素抵抗的药剂的筛选方法。 还提供了通过施用有效量的针对S6激酶1特异性的抑制剂来治疗胰岛素抵抗的方法。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.029 秒)
